| [1] |
Tsubota S, Kadomatsu K. Origin and initiation mechanisms of neuroblastoma[J]. Cell Tissue Res, 2018, 372(2): 211-221.
doi: 10.1007/s00441-018-2796-z
pmid: 29445860
|
| [2] |
Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma[J]. Lancet, 2007, 369: 2106-2120.
doi: 10.1016/S0140-6736(07)60983-0
pmid: 17586306
|
| [3] |
Brodeur GM, Marris JM. Neuroblastoma[M]//Pizzo PA, Poplack BG. Principles and practice of pediatric oncology, 5th ed. Philadelphia: Lippincott Williams &Wilkins; 2006: 933-970.
|
| [4] |
Gurney JG, Ross JA, Wall DA, et al. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992 [J]. J Pediatr Hematol Oncol, 1997, 19: 428.
doi: 10.1097/00043426-199709000-00004
|
| [5] |
Uemura S, Ishida T, Thwin KKM, et al. Dynamics of minimal residual disease in neuroblastoma patients[J]. Front Oncol, 2019, 9: 455.
doi: 10.3389/fonc.2019.00455
|
| [6] |
鲍萍萍, 李凯, 吴春晓, 等. 2002-2010年上海市户籍儿童恶性实体肿瘤发病特征和变化趋势分析[J]. 中华儿科杂志, 2013, 51(4): 288-294.
|
| [7] |
Liang WH, Federico SM, London WB, et al. Tailoring therapy for children with neuroblastoma on the basis of risk group classification: past, present, and future[J]. JCO Clin Cancer Inform, 2020, 4: 895-905.
|
| [8] |
Tas ML, Reedijk AMJ, Karim-Kos HE, et al. Neuro-blastoma between 1990 and 2014 in the Netherlands: increased incidence and improved survival of high-risk neuroblastoma[J]. Eur J Cancer, 2020, 124: 47-55.
doi: 10.1016/j.ejca.2019.09.025
|
| [9] |
Pastor ER, Mousa SA. Current management of neuro-blastoma and future direction[J]. Crit Rev Oncol Hematol, 2019, 138: 38-43.
doi: 10.1016/j.critrevonc.2019.03.013
|
| [10] |
Gains J, Mandeville H, Cork N, et al. Ten challenges in the management of neuroblastoma[J]. Future Oncol, 2012, 8(7): 839-58.
doi: 10.2217/fon.12.70
|
| [11] |
Shohet J, Foster J. Neuroblastoma[J]. BMJ, 2017, 357: j1863.
|
| [12] |
Zage PE. Novel therapies for relapsed and refractory neuroblastoma[J]. Children (Basel), 2018, 5(11): 148.
|
| [13] |
Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma[J]. Cancer Invest, 2007, 25(1): 67-77.
|
| [14] |
Kholodenko IV, Kalinovsky DV, Doronin II, et al. Neuroblastoma origin and therapeutic targets for immune therapy[J]. J Immunol Res, 2018, 2018: 7394268.
|
| [15] |
Voeller J, Sondel PM. Advances in anti-GD2 immuno therapy for treatment of high-risk neuroblastoma[J]. J Pediatr Hematol Oncol, 2019, 41(3): 163-169.
doi: 10.1097/MPH.0000000000001369
|
| [16] |
Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody[J]. J Immunol, 1990, 144(4): 1382-1386.
pmid: 2303711
|
| [17] |
Eusa Pharma UK. Legal Category[EB/OL]. [2021-12-07]. https://www.medicines.org.uk/emc/product/9441/smpc.
|
| [18] |
Siebert N, Eger C, Seidel D, et al. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2[J]. MAbs, 2016, 8(3): 604-616.
doi: 10.1080/19420862.2015.1130196
|
| [19] |
European Medicines Agency. Assessment report - Dinutuximab beta Apeiron[EB/OL]. https://www.ema.europa.eu/en/documents/assessment-report/dinutuximab-beta-apeiron-epar-public-assessment-report_en.pdf.
|
| [20] |
Ladenstein R, Potschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(12): 1617-1629.
doi: S1470-2045(18)30578-3
pmid: 30442501
|
| [21] |
Ladenstein R, Potschger U, Valteau-Couanet D, et al. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1)[J]. Cancers (Basel), 2020, 12(2): 309.
doi: 10.3390/cancers12020309
|
| [22] |
Mueller I, Ehlert K, Endres S, et al. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO[J]. Mabs, 2018, 10(1): 55-61.
doi: 10.1080/19420862.2017.1402997
pmid: 29120699
|
| [23] |
Lode HN. Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial[J/OL]. J Clin Oncol, 37, 2019 (suppl): abstr 10014. [2021-12-07]. https://meetings.asco.org/abstracts-presentations/170960.
|
| [24] |
Garaventa A, Parodi S, De Bernardi B, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry[J]. Eur J Cancer, 2009, 45(16): 2835-2842.
doi: 10.1016/j.ejca.2009.06.010
pmid: 19616426
|
| [25] |
European Medicines Agency. Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)[EB/OL]. [2021-12-07]. https://www.ema.europa.eu/en/documents/product-information/qarziba-epar-product-information_en-0.pdf
|
| [26] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)肿瘤放化疗相关中性粒细胞减少症规范化管理指南(2021)[J]. 临床肿瘤学杂志, 2021, 26(7): 638-648.
|
| [27] |
Barone G, Barry A, Bautista F, et al. Managing adverse events associated with dinutuximab beta treatment in patients with high-risk neuroblastoma: practical guidance[J]. Paediatr Drugs, 2021, 23(6): 537-548.
doi: 10.1007/s40272-021-00469-9
|
| [28] |
Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management[J]. Kidney Int, 2017, 92(1): 37-46.
doi: S0085-2538(17)30073-X
pmid: 28318633
|
)
